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Despite their apparent lack of catalytic activity, pseudokinases are essential signaling molecules. 
Here, we describe the structural and dynamic properties of pseudokinase domains from the Wnt-
binding receptor tyrosine kinases (PTK7, ROR1, ROR2, RYK), which play important roles in 
development. We determined structures of all pseudokinase domains in this family, and found 
that they share a conserved inactive conformation in their activation loop that resembles the 
autoinhibited insulin receptor kinase (IRK). They also have inaccessible ATP binding pockets, 
occluded by aromatic residues that mimic a cofactor-bound state. Structural comparisons 
revealed significant domain plasticity, and alternative interactions that substitute for absent 
conserved motifs. The pseudokinases also showed strikingly similar dynamic properties to IRK. 
Despite the inaccessible ATP site, screening identified ATP competitive type-II inhibitors for 
ROR1. Our results set the stage for an emerging therapeutic modality of “conformational 
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As receptor tyrosine kinase (RTK) signaling mechanisms have become increasingly well 
understood (Lemmon and Schlessinger, 2010), those mediated by the subset of RTKs thought 
to lack kinase activity remain largely enigmatic (Manning et al., 2002; Mendrola et al., 2013). 
Approximately 10% of the >500 predicted human protein kinases are classed as 
pseudokinases, assumed to lack phosphotransferase activity because of substitutions of 
conserved and essential catalytic residues (Boudeau et al., 2006; Manning et al., 2002). Five of 
the 58 human RTKs fall into this category: ErbB3/HER3, protein tyrosine kinase 7 (PTK7)/colon 
carcinoma kinase 4 (CCK4), EphB6, EphA10, and SuRTK106 (which lacks an extracellular 
region and was not included in our study). Three additional RTKs (ROR1, ROR2 and RYK) have 
substitutions in conserved motifs and lack both kinase activity (Debebe and Rathmell, 2015; 
Gentile et al., 2011; Katso et al., 1999) and ATP binding (Murphy et al., 2014). These ‘RTK 
pseudokinases’ are depicted in Fig. 1A, and the pseudokinase domain sequences are 
compared in Fig. S1. 
 Beyond the basic question of how RTKs can signal without kinase activity, strong links of 
RTK pseudokinases to disease have prompted significant interest in developing therapeutic 
approaches to inhibit their signaling functions (Bailey et al., 2015; Kung and Jura, 2019). ErbB3 
is associated with lung, colon, gastric, and other cancers (Amin et al., 2010; Jaiswal et al., 
2013), especially in resistance to inhibitors of other EGFR family members. PTK7, ROR1/2, and 
RYK are all involved in Wnt signaling (Green et al., 2014; Karvonen et al., 2018; Peradziryi et 
al., 2012), and elevation of their expression is associated with cancer development and 
metastasis in several hematological and solid tumors (Debebe and Rathmell, 2015; Karvonen et 
al., 2018). EphB6 and EphA10 are also reported to play important roles in tumorigenesis (Liang 
et al., 2019; Nagano et al., 2014). Antibodies targeting the ErbB3 extracellular region are in 
clinical development for several solid tumors (Jacob et al., 2018). ROR1 antibodies are being 
tested clinically in chronic lymphocytic leukemia (CLL) and other cancers (Choi et al., 2018; 
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Choi et al., 2015), as is a small molecule claimed to target the ROR1 extracellular region (Liu et 
al., 2019). PTK7 is also the target of an antibody-drug conjugate in clinical development 
(Damelin et al., 2017; Katoh, 2017). No validated pharmacological agents that target 
intracellular regions of RTK pseudokinases have been described, however – largely because 
their mechanistic role in signaling is poorly understood. 
 The nucleotide binding properties of RTK pseudokinase domains vary. Those from 
PTK7, ROR1/2, and RYK all fail to bind ATP (Murphy et al., 2014), whereas those from ErbB3 
and EphB6 bind ATP quite strongly (Jura et al., 2009; Murphy et al., 2014; Shi et al., 2010). 
ErbB3 also displays low level kinase activity (Shi et al., 2010; Steinkamp et al., 2014), inhibition 
of which does not block signaling (Novotny et al., 2016; Shi, 2012). Without phosphotransferase 
activity, pseudokinases are thought to signal by allosterically regulating binding partners (Zeqiraj 
and van Aalten, 2010). To help understand this role, we combined crystallographic, biophysical, 
and chemical biology studies. We show that RTK pseudokinase domains adopt structures 
closely related to the inactive state of their closest kinase-active homologue, and with 
comparable dynamics – suggesting a similar propensity for conformational changes. We also 
demonstrate that a pseudokinase domain that fails to bind ATP can nonetheless be targeted 
with small molecules that bind its vestigial ATP-binding site. The insight provided here into the 
structure and dynamics of pseudokinase domains suggests approaches for defining the 
mechanisms of their function and for targeting them pharmacologically. 
 
RESULTS AND DISCUSSION 
As a first step, we aimed to establish a comprehensive structural description of RTK 
pseudokinases – adding to structures of the ErbB3 (Jura et al., 2009; Shi et al., 2010) and 
ROR2 (Artim et al., 2012) pseudokinase domains. We determined crystal structures of 
pseudokinases from the remainder of the Wnt-binding RTK (PTK7/ROR/RYK) family, and also 
modeled the Eph RTK pseudokinases. 
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The activation loops of PTK7, ROR, and RYK pseudokinase domains mimic 
autoinhibitory interactions seen in inactive IRK 
We determined crystal structures of the PTK7 and RYK pseudokinase domains (to 1.95 Å and 
2.38 Å respectively) plus that of ROR1 bound to a small molecule (described in a later section), 
as summarized in Table 1. These pseudokinase domains all contain a YxxxYY motif (or its 
vestiges) in the activation loop, similar to that in the insulin receptor kinase domain (IRK). The 
activation loop conformations also closely resemble that of inactive, autoinhibited, IRK (Fig. 1B) 
– immediately raising the question as to what activity or property is ‘autoinhibited’ in the 
pseudokinases. Inactive IRK is autoinhibited by simultaneous projection of a key tyrosine side 
chain (Y1162) into the protein substrate-binding site and occlusion of the ATP-binding site by 
the IRK DFG motif (Hubbard et al., 1994). The PTK7, RYK, and ROR pseudokinases all 
similarly place a tyrosine in precisely the same location as Y1162 of IRK (Fig. 1B), and the 
YxxxYY motif configuration (FxxxYH in RYK) is highly conserved. By contrast, the ErbB3 
activation loop adopts a different conformation – instead resembling the inactive EGFR kinase 
domain (Jura et al., 2009; Shi et al., 2010). ErbB3 does place its single activation loop tyrosine 
(Y848; not conserved in EGFR) in a very similar location to Y1162 in IRK, however (Littlefield et 
al., 2014), suggesting that projecting an activation loop tyrosine into the (protein) substrate 
binding site may be common across RTK pseudokinases (Fig. 1C). 
 The ATP-binding site of inactive IRK is occluded in two ways (Hubbard et al., 1994). 
First, the side-chain of the DFG phenylalanine (F1151) projects into the adenine ring binding 
site (Fig. 1D: IRK inactive). Second, the main chain following the DFG motif occludes the 
binding site for the ATP β- and γ-phosphate groups (Fig. 1D). This is the ‘DFG-out’ conformation 
(Huse and Kuriyan, 2002; Modi and Dunbrack, 2019), frequently seen in inactive kinases – in 
which the aspartate side-chain (D1150) is also oriented away from the active site so that is 
cannot coordinate Mg2+. In active kinases, the DFG motif instead adopts an ‘in’ conformation, 
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allowing Mg2+ coordination and repositioning the phenylalanine side-chain to allow ATP binding 
and to complete the so-called regulatory spine (Fig. S2) or ‘R-spine’ (Kornev and Taylor, 2010). 
The Wnt-binding RTK pseudokinases all have an altered DFG motif (‘ALG’ in PTK7, ‘DLG’ in the 
RORs and ‘DNA’ in RYK; Fig. 1D). The conformation of this altered motif is always closer to 
‘DFG-out’ than ‘DFG-in’ (Fig. 1D). As a result, each R-spine is broken (Fig. S2) – although in a 
different way for RYK than for PTK7 or ROR2 (which more closely resemble inactive IRK). 
Moreover, the leucine side-chains in the PTK7 ‘ALG’ motif (L949) and the ROR2 ‘DLG’ motif 
(L634) occlude the ATP-binding site (Fig. 1D). RYK is an exception, as its ‘DNA’ motif lacks a 
corresponding hydrophobic side-chain – although the main chain after this motif passes through 
(and occludes) the β/γ phosphate group-binding region (Fig. 1D). In contrast with the Wnt 
pseudokinase RTKs, the ErbB3 DFG motif adopts an ‘in’ conformation that completes the R-
spine and leaves the ATP-binding site open to allow nucleotide binding (Figs. 1D and S2). 
 
Aromatic side-chains from the hinge region occlude the PTK7, ROR, and RYK ATP-
binding sites 
ATP binding to PTK7 and ROR2 is prevented by projection of a tyrosine side-chain from the 
β5/αD hinge region (Y877 and Y555 respectively) into the adenine ring binding site (Fig. 1D). 
This position is two residues C-terminal to the gatekeeper, and is a tyrosine in ~50% of tyrosine 
kinases – although replaced by leucine (L1078) in IRK. The side-chain at this position typically 
projects away from the ATP binding site (as for L1078 in IRK and Y770 in ErbB3; Fig. 1D). The 
alternative side-chain orientation in PTK7 and ROR2 results from a rotation of their N-lobes 
about the β5/αD hinge (Fig. S3A,B). RYK does not undergo this N-lobe rotation (Fig. S3C), 
allowing its corresponding tyrosine (Y413) to adopt the canonical orientation (Fig. 1D). The RYK 
adenine ring binding site is instead occluded by the side-chain of a phenylalanine (F362) in the 
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altered β3 VAIK motif (AFVK in RYK). A leucine at this position in PTK7 (L828 in its VLVK 
variant of the VAIK motif) also contributes to ATP-binding site occlusion. 
 Whereas the ATP binding sites in RTK pseudokinases are occluded by side-chains from 
multiple motifs, the IRK ATP-binding site is only obstructed by its DFG motif (Figs. 1D and S4A), 
suggesting that simply flipping the DFG motif from ‘out’ to ‘in’ might allow ATP binding. Indeed, 
IRK can bind Mg2+-ATP without activation loop phosphorylation (Till et al., 2001) as can be seen 
using differential scanning fluorimetry (DSF). DSF monitors the influence of ligand binding on 
the melting temperature (TM) of a protein, as reported by increased fluorescence of SYPRO 
Orange as it binds to thermally unfolded protein (Fedorov et al., 2012). Binding of Mg2+-ATP to 
unphosphorylated IRK destabilized the kinase domain by ~3.5˚C (Fig. S4B) – rather than 
stabilizing – which may reflect disruption of the autoinhibitory activation loop interactions 
described above. In contrast to IRK, the PTK7, ROR1, ROR2, and RYK pseudokinase domains 
showed no significant stability change upon adding 5 mM Mg2+-ATP (Fig. S4B), suggesting no 
binding, in agreement with previous work (Murphy et al., 2014). Moreover, a D644A mutation in 
ROR2 (equivalent to D1161A in IRK, which promotes ATP binding) failed to restore ATP 
binding. 
 Another important difference between IRK and the Wnt-binding RTK pseudokinases is 
revealed by comparing their catalytic spines (‘C-spines’). The ‘C-spine’ is a non-contiguous 
hydrophobic motif defined by Kornev and Taylor (Kornev and Taylor, 2010). In ATP-bound 
active kinases, it is completed by the adenine ring of bound ATP, as seen in PKA and active 
IRK in Fig. S2. In an inactive kinase, by contrast, the C-spine is broken (see inactive IRK in Fig. 
S2) and the side-chain of the DFG-motif phenylalanine (from the R-spine) projects into the gap. 
Interestingly, the C-spine is fully contiguous in PTK7, ROR2 and RYK despite no direct 
contribution from R-spine (DFG motif) residues or ATP (Fig. S2) – although the side-chain of the 
ALG/DLG motif leucine does abut the intact C-spine in PTK7 and ROR2. 
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PTK7, ROR, and RYK pseudokinases adopt different ‘hybrid’ conformations stabilized by 
unique sets of interactions 
Although the PTK7, ROR, and RYK pseudokinase domains all closely resemble inactive IRK in 
their activation loop configurations (Fig. 1B), they vary substantially in αC helix position (Fig. 2A) 
and in other structural features, details of which can be described as follows. 
PTK7:  Although PTK7 appears autoinhibited by its activation loop (and hinge tyrosine), it 
has an active-like ‘in’ αC disposition (Fig. 2A). As a result, the distance between the side-chains 
of the conserved αC glutamate (E846) and the VAIK motif β3 lysine (K830) is just 2.7 Å. This 
allows the αC/β3 salt bridge – a hallmark of active kinases – to form (Fig. 2B), and places K830 
so that it could support ATP binding if the ATP-binding site were not occluded. PTK7 thus 
adopts an unusual ‘pseudo’ active-like kinase domain conformation. 
ROR2:  The ROR2 αC helix adopts the ‘out’ position as in inactive IRK (Fig. 2A). The side-
chains of the αC glutamate (E524) and β3 lysine (K507) are therefore too far apart (~5 Å) for the 
hallmark αC/β3 salt bridge of active kinases to form (Fig. 2C) – and the β3 lysine (K507) is >7 Å 
away from where the ATP phosphates would reside in a putative nucleotide-bound state (Artim 
et al., 2012). A hydrogen bond between D633 in the degenerated ROR2 DFG motif (DLG) and 
R528 in αC also connects these two motifs in an unusual way (Fig. 2C). 
RYK:  The RYK pseudokinase domain has several unique structural features. First, as in 
PTK7, its αC helix adopts an active-like ‘in’ position (Fig. 2A), apparently ‘pushed’ into this 
position by a 2.5-turn α-helix (αB) at the domain’s amino-terminus (Fig. 2D). This arrangement 
is reminiscent of the EphB2 kinase domain (Wybenga-Groot et al., 2001) and involves intimate 
clustering of hydrophobic side-chains at the αB/αC interface (Fig. 2D, left). Surprisingly, 
although the conserved β3 lysine (K364) is retained in RYK’s degenerated VAIK motif (AFVK), 
and αC is ‘in’, the αC/β3 salt bridge that is a hallmark of active kinases does not form in RYK 
(Fig. 2D, right). Instead, K364 forms a predicted salt-bridge (2.6 Å) with D483 in RYK’s 
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degenerated DFG (DNA) motif, and the αC glutamate (E381) is close (3.0 Å) to R488 in the 
activation loop (three residues C-terminal to the degenerated DFG motif). The absence of a 
large hydrophobic side-chain in RYK’s degenerated DFG motif also appears to be compensated 
for by the positioning of F491 in the small helix C-terminal to this motif (Fig. S4A). In addition, 
the presence of a glutamine (Q337) in place of the first glycine of the glycine rich loop in RYK 
contributes to steric exclusion of RYK’s ATP binding site (Fig. S4A). 
 
Differences in Eph pseudokinase domain autoinhibition 
To extend these comparisons across the RTK pseudokinases, we modeled the EphA10 and 
EphB6 pseudokinase domains, so far of unknown structure. Apart from EphA10 and EphB6, the 
remaining 12 human ephrin receptors (Ephs) are catalytically active (Liang et al., 2019). They 
are regulated by phosphorylation of key juxtamembrane (JM) tyrosines, which relieves 
intramolecular autoinhibition to allow trans-autophosphorylation of a conserved activation loop 
tyrosine (Hornbeck et al., 2015) that corresponds to Y1162 in IRK. EphA10 retains this 
conserved activation loop tyrosine, but not the regulatory JM tyrosines. Conversely, EphB6 
retains the regulatory JM tyrosines but not the activation loop tyrosine (and has an unusually 
short activation loop). In the few published Eph kinase structures in inactive conformations 
(Dong et al., 2014; Kung et al., 2016; Overman et al., 2014), the activation loop tyrosine is 
ordered and projects into the substrate binding site like Y1162 of inactive IRK. Similarly, our 
EphA10 pseudokinase model, (based on EphB3; see STAR Methods) places this tyrosine 
(Y801) in the autoinhibitory location (Fig. 3A,B). Y801 simultaneously contacts the arginine 
close to the end of the catalytic loop (R774 in EphA10) and an adjacent EphA10-specific 
histidine (H775) – substituting for interaction with the (absent) HRD aspartate (Fig. 3B). This 
IRK-like docking of Y801 constrains the EphA10 activation loop so that the backbone of the 
DFG motif (GFG in EphA10) passes through and occludes the ATP-binding site as in IRK (Fig. 
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3C). No additional occlusion of the ATP-binding site from the β5/αD hinge is seen, suggesting 
that EphA10 shares IRK’s ATP-binding properties. 
 EphB6 lacks 14 activation loop residues (including the conserved tyrosine), so cannot 
adopt the inactive-like conformation seen in IRK and EphA10. Instead, the shortened and 
unrestrained EphB6 activation loop adopts an active-like conformation in our models (Fig. 3), 
leaving EphB6 free to bind ATP as reported experimentally (Becher et al., 2013; Murphy et al., 
2014) – with a possible positive contribution from R813 (Fig. 3C). Thus, whereas EphA10 
seems to resemble IRK and the Wnt-binding RTK pseudokinases, EphB6 appears to resemble 
ErbB3 in having an unprotected ATP-binding site. 
 
Pseudokinases and kinases display similar conformational dynamics 
It has been hypothesized that pseudokinases function as allosteric regulators or scaffolding 
molecules in cell signaling (Kung and Jura, 2019; Reiterer et al., 2014; Zeqiraj and van Aalten, 
2010), which might require dynamic transitions between different conformational states as seen 
for canonical kinases (Huse and Kuriyan, 2002; Kornev and Taylor, 2015). Alternatively, 
pseudokinase domains might be more static than other kinase domains, allowing them to serve 
as rigid scaffolds – a view suggested by the fully occluded ATP-binding sites, well-defined 
autoinhibitory activation loops, and additional intramolecular interactions seen in PTK7, ROR2 
and RYK but not in other protein kinases. To distinguish between these possibilities, we used 
hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS) to compare 
exchange dynamics of the pseudokinase domains with those of unphosphorylated, inactive IRK. 
IRK activation requires the unphosphorylated activation loop to explore multiple 
conformations. These fluctuations can transiently reverse autoinhibition so that Mg2+-ATP and 
substrate tyrosine can bind (Hubbard, 2013) – and the kinase can trans-phosphorylate its 
neighbor in an insulin receptor dimer to promote signaling. HDX-MS studies of IRK (Fig. 4A) 
illustrate this dynamic conformational exploration, with backbone amide protons in the YxxxYY 
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motif-containing activation loop becoming almost completely exchanged within ~1 minute. Other 
regions of IRK are also quite dynamic, whereas the HRD motif (which harbors the catalytic base 
aspartate) and the β5/αD hinge (between N- and C-lobes) show the slowest HDX rates (Fig. 
4A,B; Table S1). A similar overall dynamic picture has been reported for other protein kinases 
studied by HDX-MS (Bunney et al., 2018; Hsu et al., 2008; Iacob et al., 2009; Loving and 
Underbakke, 2019; Shi et al., 2006; Sours et al., 2008; Tsutsui et al., 2016), so IRK appears 
typical. 
 Far from being more static than typical kinases, all of the pseudokinase domains studied 
here show very similar dynamic characteristics to IRK (Fig. 4C). Most importantly, the activation 
loops of the pseudokinase domains – which contain the DFG and YxxxYY motifs – all showed 
very similar HDX rates to those of IRK. The pseudokinases also share with IRK a relatively low 
rate of exchange in the HRD motif. Other general trends are also similar, although each 
pseudokinase does display some unique features, such as increased β2/β3 loop exchange in 
PTK7 and ROR2, and reduced exchange in αC peptides for all pseudokinases compared with 
IRK. Regions in the C-lobe (notably αF and beyond) show much more variability from domain to 
domain, likely owing to differences in helix and loop lengths. In Fig. 4D, differences between a 
mean ‘exchangeability index’ for the pseudokinase domains as a group (see STAR Methods) 
and HDX measured for IRK are plotted on the IRK structure. For most of the structure, the 
difference is within two standard deviations of the mean for pseudokinases (white). Differences 
exceed 2σ only in αC and the glycine-rich (β1/β2) loop – which both show slightly less exchange 
in the pseudokinases (colored darker grey). By contrast, the β5/αD loop (leading into αD) and 
helix αI both show slightly higher exchange in pseudokinases (colored orange). 
 These results demonstrate that structural elements in the RTK pseudokinase domains 
are not significantly more rigid than in catalytically active counterparts such as IRK. This in turn 
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suggests that the pseudokinases may maintain conformational switching-based regulatory 
mechanisms seen with active kinases, which could control scaffolding functions in signaling. 
 
The intracellular pseudokinase domain elicits signaling functions 
A major challenge in studying the Wnt-binding RTK pseudokinases has been the availability of 
experimental contexts for structure/function analysis of signaling (Green et al., 2014; Karvonen 
et al., 2018). Moreover, some in vivo studies have led to inferences that the intracellular 
pseudokinase domains of Wnt-binding RTKs are not required for signaling (Green et al., 2014; 
Hayes et al., 2013; Inoue et al., 2004; Stricker et al., 2017) – although this likely reflects Wnt 
sequestration by the extracellular regions of the overexpressed constructs. 
 Using an approach frequently employed in studies of RTKs (Collins et al., 1988; 
Warmuth et al., 2007), we expressed ROR1, ROR2 and PTK7 in the interleukin-3 (IL3) 
dependent BaF3 murine pro-B cell line (Fig. S5A). Whereas parental BaF3 cells die following 
IL3 withdrawal, a significant number of those expressing ROR2 survived in the absence of IL3 
(Fig. S5B), and those expressing PTK7 showed some improved survival, consistent with 
previous studies (Prebet et al., 2010). In addition, ROR1-expressing cells (Fig. 5A) ultimately 
achieved IL3 independent proliferation (Fig. 5B) – consistent with the contribution of ROR1 (but 
not ROR2) to CLL and other hematological malignancies (Daneshmanesh et al., 2013; 
Karvonen et al., 2018). Intriguingly, the ROR1-expressing cells also responded to Wnt5a 
stimulation with significant elevation of ERK, AKT, and SRC phosphorylation (Fig. 5C), whereas 
no such response was seen in parental BaF3 cells or with ROR2 (Fig. S5C). These findings are 
consistent with studies of ROR1 signaling in a lymphoblastic leukemia cell-line (Bicocca et al., 
2012) as well as other reports (Karvonen et al., 2019; Yamaguchi et al., 2012; Zhang et al., 
2019). To ask whether the intracellular pseudokinase domain of ROR1 is required for these 
responses, we expressed a form of ROR1 that lacks its entire intracellular region (ROR1∆ICR). 
Despite strong expression (Fig. 5A), ROR1∆ICR lacked the ability to promote IL3-independent 
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proliferation of BaF3 cells or to support Wnt5a-induced ERK, AKT, and SRC activation (Fig. 
5B,C). Mutating the YxxxYY motif in the ROR1 activation loop to FxxxFF also abolished the 
ability of ROR1 to support BaF3 cell proliferation, as did mutating the VAIK β3 lysine (K506) to 
alanine (Fig. 5D,E). These data argue that the intracellular region of ROR1 (and those of other 
RTK pseudokinases) can provide important signaling functions despite lacking 
phosphotransferase activity. We were unable to detect any residual kinase activity for ROR1 
(Fig. S5D,E) – as also reported by others (Murphy et al., 2014). We therefore suggest that the 
mutations analyzed in Fig. 5 impair ROR1 signaling function by altering the conformation of its 
pseudokinase domain. Given the status of ROR1 and the other RTK pseudokinases as 
therapeutic targets, these findings prompted us to investigate targeting them with small 
molecules that might similarly modulate conformation. Our goal is to identify small molecules 
that modulate the scaffolding and/or allosteric functions of pseudokinase domains by inducing 
conformational changes – following precedents set with the TYK2 (Wrobleski et al., 2019), 
STRAD (Zeqiraj et al., 2009) and KSR (Dhawan et al., 2016) pseudokinases, as well as 
catalytically active kinases such as Aurora A (Gustafson et al., 2014). 
 
Selective small molecule binders of the ROR1 pseudokinase domain 
To identify small molecules that bind the ROR1, ROR2, PTK7, and RYK pseudokinase 
domains, we again used DSF, screening a total of 1486 compounds from the published protein 
kinase inhibitor set and the FDA-approved drug set from Selleckchem (see Table S2). The cut-
off value for identifying ‘hits’ was thermal stabilization of ±2˚C (Fig. 6A). Despite the relatively 
large and kinase inhibitor-focused screening set, we failed to identify any hits for PTK7, ROR2, 
or RYK. For ROR1, however, we identified two closely related inhibitors that significantly 
increased TM – indicating strong binding. These were ponatinib (O'Hare et al., 2009), a multi-
targeted kinase inhibitor approved by the FDA for chronic myeloid leukemia (CML) and 
Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), and GZD824 (Ren et 
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al., 2013) – which is structurally related. Both are BCR-ABL inhibitors that retain the ability to 
inhibit T315I gatekeeper-mutated ABL. Ponatinib and GZD824 stabilized ROR1 by 4.1˚C and 
6.0˚C respectively (Fig. 6A), but did not bind ROR2, RYK, or PTK7. The two inhibitors are 
typical type-II inhibitors that likely induce a particular DFG-out conformation. The compact 
nature of their alkyne linker (Fig. 6B) is key for binding to T315I-mutated ABL (it is interesting to 
note that ROR1 has a phenylalanine at the gatekeeper position). To validate ponatinib and 
GZD824 as ‘hits’, and to exclude the possibility that they simply interfere in the DSF assay, we 
measured TM for the ROR1 pseudokinase domain at a series of GZD824 concentrations (Fig. 
6C). The resulting curve showed clear saturation (at ~10 µM) and an IC50 value of ~1 µM (for a 
ROR1 concentration of 2 µM in the assay) – arguing that KD is submicromolar. Using a cellular 
thermal shift assay or CETSA (Martinez Molina et al., 2013), we further showed that both 
ponatinib and GZD824 engage (and stabilize) full-length ROR1 in BaF3 cells when added at 
10 µM (Fig. 6D,E). Maximum stabilization of ROR1 in these assays was achieved with ~2 µM 
GZD824 or ~5 µM ponatinib (Fig. S6). These data suggest that both inhibitors form 
stoichiometric complexes with ROR1. Moreover, the fact that neither compound binds 
detectably to the ROR2, PTK7, or RYK pseudokinase domains demonstrates clear selectivity 
within the Wnt pseudokinase family – although GZD824 and ponatinib are known to inhibit a 
range of other tyrosine kinases. Importantly, as discussed below, ROR1-dependent activation of 
ERK and AKT phosphorylation by Wnt5a is inhibited at the same concentrations of ponatinib 
and GZD824 that maximally stabilize ROR1 in cells. 
 
Binding of ponatinib or GZD824 induces conformational changes in the ROR1 
pseudokinase domain 
To investigate whether binding of ponatinib or GZD824 to the ROR1 pseudokinase domain 
induces conformational changes, we again turned to HDX-MS. Adding excess ponatinib or 
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GZD824 to the ROR1 pseudokinase domain led to significant protection from exchange in 
peptides close to the putative ATP-binding site (Fig. 7A,B and Fig. S7A,B), demonstrating that 
the occluded ATP-binding site of ROR1 can still accommodate kinase inhibitor-like molecules 
(presumably with associated conformational changes). Binding of ponatinib or GZD824 caused 
significant HDX protection in helix αC, αE, the β5/αD hinge region, the HRD motif, and the DFG 
(DLG) motif at the beginning of the activation loop – all regions adjacent to the vestigial ATP-
binding site. By contrast, several more remote peptides showed increased backbone amide 
exchange upon inhibitor binding (red in Figs. 7A and S7A,B), arguing that the inhibitors induce 
significant changes in the pseudokinase domain’s conformation. Regions affected in this way 
(red bars in Fig. 7A) included peptides in the β1/β2 (glycine-rich) loop region, part of strand β3, 
and much of the ROR1 activation loop – where inhibitor binding increases HDX in an already 
quite dynamic region of ROR1 (e.g. Fig. 7B, peptide iv), arguing that it destabilizes 
autoinhibitory interactions. 
 
Crystal structure of the ROR1 pseudokinase domain bound to ponatinib 
To directly visualize the mode of inhibitor binding to this pseudokinase, we co-crystallized the 
ROR1 pseudokinase domain with ponatinib and determined a 1.94 Å crystal structure (Fig. 7C). 
The structure confirmed that ponatinib binds to the region corresponding to ROR1’s ATP-
binding site, contacting all of the sites protected in HDX studies. Ponatinib binds ROR1 with the 
same binding mode seen when it binds ABL (O'Hare et al., 2009), as shown in Fig. S7C. The 
narrow alkyne linker of ponatinib, key for allowing it to bind T315I-mutated ABL, abuts the bulky 
gatekeeper phenylalanine (F552) side-chain in ROR1 (Fig. 7C inset). The structure of the 
ponatinib-bound ROR1 pseudokinase domain is very similar to that for ROR2 (which does not 
bind ponatinib or GZD824 yet shares 68% sequence identity). The configuration of the ROR1 
activation loop YxxxYY motif closely resembles that of ROR2, RYK, PTK7 and inactive IRK in 
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the static crystallographic view, but our HDX data (Fig. 7A,B) argue that binding of ponatinib or 
GZD824 significantly increases its solvent accessibility and dynamics. Moreover, the C-terminal 
part of the activation loop – immediately following the YxxxYY motif – was disordered in the 
ROR1/ponatinib complex structure, suggesting that accommodating ponatinib partly disrupts 
autoinhibitory docking of the activation loop in this region. 
Another ponatinib-induced conformational change is seen in the DFG motif (DLG in 
ROR1/2). Ponatinib restrains this motif in ROR1 so that the leucine side-chain is disordered and 
the DLG aspartate (D633) side-chain is displaced (by ponatinib’s trifluoromethylphenyl group) 
towards H613 of the HRD motif (see Fig. 7C inset). This forces ROR1’s DLG motif into the 
same conformation seen for the DFG motif in ponatinib-bound ABL (O'Hare et al., 2009) – 
typical of that in kinases bound to type-II inhibitors (Modi and Dunbrack, 2019). 
The largest-scale difference between the structures of the ROR1/ponatinib complex and 
ROR2 (which does not bind ponatinib) is a rotation (~20˚) of the entire N-lobe about an axis 
(yellow rod in Fig. 7D) nearly coincident with strand β4. Ponatinib appears to simultaneously 
‘push’ on the left-hand side of the N-lobe (near β1 and the β5/αD hinge) and ‘pull’ on its right-
hand side (near αC) to achieve this rotation. Ponatinib displaces the side-chain of the β5/αD 
hinge tyrosine (Y554 in ROR1, Y555 in ROR2) that occludes ROR2’s ATP-binding site, as 
indicated by the red arrow on the left of Fig. 7D – inserting its imidazo(1,2-b)pyridazine moiety 
into that pocket. At the same time, ponatinib (docked onto the C-lobe) associates intimately with 
helix αC of ROR1, through an interaction between the nitrogen of its amide linker and E523 in 
αC plus van der Waal’s contacts with the (hydrophobic) side-chains of L526, M527, and L530 in 
αC. All the corresponding residues are solvent-exposed in ROR2 (E524, L527, R528, and 
L531). Importantly, an arginine at position 528 of ROR2 (replaced by M527 in ROR1 – which 
contacts ponatinib) likely explains why ponatinib binds only ROR1, and not ROR2. An arginine 
in this position would interfere with ponatinib/αC interactions. 
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Together with our HDX-MS studies, this comparison of the ponatinib-bound ROR1 and 
unliganded ROR2 pseudokinase domain structures reveals one way in which a kinase inhibitor-
like small molecule binder can modulate the conformation of a pseudokinase domain. Many 
effectors and activators bind to the N-lobe region of other kinases that is the focus of the 
conformational changes described here (Jura et al., 2011). Any similar mode of interaction that 
ROR1 participates in will thus be significantly affected by ponatinib or GZD824 binding. 
Ponatinib and GZD824 may therefore serve as pharmacologically privileged potential starting 
points for developing selective small molecule ROR1 interactors that could induce sufficiently 
extensive conformational changes in the pseudokinase domain to impair scaffolding functions of 
ROR1 in disease. Although efforts to investigate the effects of these inhibitors on the ROR1-
mediated signaling seen in Fig. 5C are currently confounded by the promiscuity of ponatinib and 
GZD824 as kinase inhibitors, both compounds clearly inhibit ROR1-dependent activation of 
ERK and AKT phosphorylation by Wnt5a (Fig. S7D) at concentrations that we know maximally 
stabilize the receptor in CETSA experiments (Fig. S6). Moreover, it is interesting to note that 
Bicocca et al. found that ponatinib robustly inhibits AKT phosphorylation in acute lymphoblastic 
leukemia cells (Bicocca et al., 2012), in which ROR1 also appears to signal to AKT and ERK. 
 
CONCLUSIONS 
Our structural and modeling studies argue that the inactive kinase domains of RTK 
pseudokinases nonetheless retain the autoinhibitory interactions seen in their kinase-active 
relatives – the Wnt-binding RTKs sharing that autoinhibitory YxxxYY activation loop motif 
conformation seen in inactive IRK. RTK pseudokinases all seem either to bind nucleotide (as in 
ErbB3 and EphB6) or to mimic an ATP-bound form (as in PTK7, ROR1/2 and RYK) – as 
reported for others (Hammaren et al., 2015; Scheeff et al., 2009). Which of these two classes 
they fall into appears to correlate with whether or not the ATP-binding site is occluded in the 
inactive conformation of their closest kinase-active homologues. 
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 One important question that arises from our results is why the pseudokinases retain the 
autoinhibitory interactions seen in their kinase-active relatives. One hypothesis is that 
pseudokinase domains function as rigid scaffolds, and the autoinhibitory interactions could 
promote rigidity (Kornev and Taylor, 2009; Murphy et al., 2014; Patel et al., 2017; Scheeff et al., 
2009). On the contrary, our HDX-MS data argue that the PTK7, ROR, and RYK pseudokinase 
domains all display similar conformational dynamics to IRK, despite mimicking an ATP-bound 
state. It is well known that canonical protein kinases such as IRK undergo transitions between 
active and (family-specific) inactive conformations (Huse and Kuriyan, 2002). The RTK 
pseudokinases are likely to have similar capabilities, providing a possible mechanism for 
controlling their ability to interact with binding partners and thus regulate signaling (Jacobsen 
and Murphy, 2017; Kung and Jura, 2019). In IRK, the inactive-to-active conformational transition 
is promoted by tyrosine phosphorylation of the activation loop YxxxYY motif (Hubbard, 2013). 
YxxxYY motif tyrosine phosphorylation has been reported for both PTK7 and ROR2 (Hornbeck 
et al., 2015), and could promote structural changes similar to those seen in IRK activation. 
Indeed, phosphorylation of the ROR1 and ROR2 pseudokinase domains has been suggested to 
be mediated by SRC recruitment (Akbarzadeh et al., 2008; Gentile et al., 2014). A related 
phosphorylation-dependent mechanism has also been described for the pseudokinase MLKL 
(mixed lineage kinase domain-like protein), where phosphorylation of the pseudokinase domain 
induces conformational changes, which control intra- and intermolecular interactions that 
regulate necroptosis (Petrie et al., 2019). Thus, pseudokinases may not only be scaffolds that 
allosterically regulate active kinases, but may in fact be regulated as conformational switches. 
As with catalytically competent kinases, the dynamic structural changes involved in 
pseudokinase function might also be modulated by small molecules that bind the ATP site and 
modulate inter- and/or intra-molecular interactions. It might be possible to exploit this 
therapeutically. Several small molecules that bind the ATP-binding site of pseudokinases have 
been reported (Dhawan et al., 2016; Kung and Jura, 2019). For example, BMS-986165, an 
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ATP-competitive inhibitor that binds the pseudokinase domain of TYK2 (a JAK family member) 
is effective in several murine models of autoimmune disease and is now in clinical testing 
(Wrobleski et al., 2019). JAK pseudokinase domains play important roles in regulating activity of 
their adjacent catalytically-competent (JH1) kinase domains, highlighted by frequent patient-
derived JAK-activating mutations in the pseudokinase domain (Shan et al., 2014). In the case of 
TYK2, the unusual ATP site of its pseudokinase domain allowed selective inhibitor design that 
resulted in outstanding JAK isoform and kinome selectivity for BMS-986165 (Moslin et al., 2019; 
Wrobleski et al., 2019). Our findings support the value of similar concerted efforts to find small 
molecule modulators of the pseudokinase RTKs. Even if modulation of the properties of the 
pseudokinase domain by small molecules proves insufficient to block pseudokinase function, 
the ligands developed for the ATP-binding site of these proteins could instead be used for 
developing proteolysis targeting chimeras (PROTACs), as reported for both kinase-active RTKs 
(Burslem et al., 2018) and the RTK pseudokinase ErbB3 (Xie et al., 2014). 
In conclusion, the results presented here demonstrate the feasibility of targeting the 
apparently inaccessible ATP site of ROR1 and related RTK pseudokinases. Given the important 
role of ROR1 and the other Wnt-binding RTKs in mediating growth signals, their selective 
targeting in this way represents a potentially valuable strategy for the development of future 
therapeutic agents.  
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LEGENDS TO FIGURES 
FIGURE 1 
Pseudokinases retain autoinhibitory interactions of the insulin receptor 
(A) Domain composition of human RTK pseudokinases, with the extracellular region above, and 
intracellular region below the membrane. Domains are listed in the legend: pseudokinase (red), 
leucine-rich (L), cysteine-rich (Cys Rich), immunoglobulin (Ig), Frizzled cysteine-rich domain (Fz 
CRD), Kringle domain (Kr), Sterile Alpha Motif (SAM), and Wnt Inhibitory Factor (WIF) domain. 
(B) Activation loops of pseudokinase domains from PTK7 (slate blue), ROR2 (magenta), and 
RYK (green) are superimposed on that of IRK (black) in the context of the IRK surface (from 
PDB: 1IRK). YxxxYY tyrosines in IRK are labeled. The ROR2 structure is chain B of PDB: 
3ZZW. 
(C) ErbB3 activation loop structure (Littlefield et al., 2014) from PDB: 4RIW, superimposed on 
the 1IRK surface as in (B), with ErbB3 colored orange. Y849 is labelled. 
(D) Close-up of residues surrounding the ATP binding site for active and inactive IRK (black), 
PTK7, ROR2, RYK, and ErbB3, colored as above. AMP-PNP is solid when seen in the relevant 
crystal structure and transparent when not. Residues from the DFG motif (and 4 residues 
beyond), the β5/αD hinge, and second residue of the VAIK motif are shown (VAVK in IRK, 
VLVK in PTK7, VAIK in ROR2, AFVK in RYK, VCIK in ErbB3). 
See also Figure S1 and Table 1. 
 
FIGURE 2 
Overall structure of pseudokinase domains 
(A) Cartoon representing pseudokinase αC helix positions. Two orthogonal views of inactive 
IRK (1IRK) are shown in grey. Helix αC of IRK, which adopts the ‘out’ position is colored black. 
 24 
Helix αC from ROR2 (3ZZW; magenta) and ErbB3 (4RIW; orange) is also ‘out’. By contrast, αC 
is ‘in’ for PTK7 (slate blue), RYK (green), and active IRK (1IR3). 
(B) PTK7 pseudokinase domain. The insert shows the predicted salt bridge between the αC 
glutamate (E846) and β3 lysine (K830). 
(C) ROR2 pseudokinase domain (chain B from 3ZZW). Insert shows absence of salt bridge 
between the αC glutamate (E524) and β3 lysine (K507), and alternate contact between D633 (in 
the DLG motif) and R528 (in αC). 
(D) RYK pseudokinase domain. Inserts show hydrophobic side-chains involved in packing 
between helices αB and αC (left) and connections between the DFG (DNA) motif region and 
helix αC (right). Interactions between D483 (in DNA motif) and the β3 lysine (K364) and 
between R488 (close to DNA motif) and αC glutamate (E381) are shown. 
Vestigial ATP-binding sites are labelled in inserts of (B-D) using a transparent AMP-PNP 
molecule positioned as in active IRK. 
See also Figure S2. 
 
FIGURE 3 
Insights into EphA10 and EphB6 pseudokinases from modeling 
(A) Activation loops in models of the EphA10 (deep red) and EphB6 (olive) pseudokinases, 
superimposed on that of IRK (black) in the context of the IRK surface (from PDB: 1IRK). Y1162 
in IRK and its EphA10 equivalent (Y801) are labeled. 
(B) Close-up of interactions involving Y801 for EphA10 (left) and Y1162 for IRK (right). Where 
Y1162 of IRK interacts with D1132 in the HRD motif and R1136 from the end of the catalytic 
loop, in EphA10 Y801 retains the arginine interaction (with R774), but interacts with a histidine 
at the very end of the catalytic loop (H775) making up for the lack of an HRD aspartate 
(replaced by glycine in EphA10). 
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(C) Close-up of residues around the ATP binding sites of EphA10 (left), and EphB6 (right), 
colored as above. An AMP-PNP molecule is shown – solid when predicted to bind and 
transparent when not. Residues are shown from the DFG motif (GFG in EphA10, and RLG in 
EphB6) – and 4 residues beyond – as well as the β5/αD hinge. 
See also Figure S3. 
 
FIGURE 4 
Comparison of pseudokinase domain dynamics by HDX 
(A) HDX data at 1 minute for unphosphorylated IRK across 73 peptides (represented as short 
horizontal lines). Lines are colored according to percent exchange at 1 min (using the scale at 
right). Secondary structure of IRK is shown at top. Data for longer timepoints are plotted in the 
lower part of the figure, with the x-axis representing the median residue number of the peptide. 
Locations of the β5/αD hinge, HRD motif, activation loop (A-loop) and YxxxYY motif are noted. 
Errors represent SD from three independent labeling experiments. 
(B) Data (1 min) from the upper part of (A) plotted on the (inactive) IRK structure using the 
same color scheme as in (A). Blue represents less, and red more, exchange. 
(C) Comparison of HDX data (mean ± SD) for PTK7 (slate blue), ROR2 (magenta), RYK (green) 
and ROR1 (cyan) pseudokinase domains with data for IRK (grey) at 10 s, 1 min, 10 min, and 
2 h. X-axis represents IRK-equivalent median residue number. IRK data are depicted as the 
range for each point. Errors represent SD from three independent labeling experiments. 
(D) Variance of ‘exchangeability index’ values – determined as in STAR Methods – for 
pseudokinases versus IRK (expressed as how many times SD/σ was the IRK value away from 
the pseudokinase mean), plotted on the inactive IRK structure. A location was assigned no color 
if within 2σ, but colored black or orange as marked if beyond 2σ (95% confidence). 
See also Figure S4 and Table S1. 
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FIGURE 5 
ROR1 signaling in BaF3 cells 
(A) ROR1 and ROR1∆ICR expression in BaF3 stable clones by anti-HA Western blot (with β-
tubulin as loading control). 
(B) BaF3 (parental), BaF3-ROR1 and BaF3-ROR1∆ICR cells were cultured without IL3 or 
Wnt5a. Cell number was counted using Trypan-blue exclusion at the indicated time points, and 
plotted (mean ± SD) for 4 independent experiments. Statistical significance is defined: 
***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05. 
(C) BaF3, BaF3-ROR1 and BaF3-ROR1∆ICR cells were serum starved overnight, and then 
treated with recombinant Wnt5a (50 ng/ml) for the indicated times. Cell lysates were 
immunoblotted with the indicated antibodies. ROR1 or ROR1∆ICR protein levels were 
determined using anti-HA blotting. A representative of three independent experiments is shown. 
(D) Proliferation of BaF3 cells expressing different ROR1 variants as noted (in the absence of 
IL3 or Wnt5a), assessed using the CellTiter-Glow 2.0 Assay 14 days after seeding, and 
expressed as a fold increase over that seen for parental BaF3 cells. Data are represented as 
mean values ± SD, for 3 biological repeats. ***p ≤ 0.001. 
(E) Assessment of stable BaF3 clones expressing (HA-tagged) wild-type ROR1, a variant with 
the activation loop YxxxYY motif mutated to FxxxFF (Y641F/Y645F/Y646F), and a K506A-
mutated variant by Western blotting with anti-HA and β-tubulin as loading control. 








Screening for small molecules that bind pseudokinase domains 
(A) Summary of DSF-based screen for small molecule binders of Wnt-binding RTK 
pseudokinases. Hits identified in the ROR1 screen are denoted with horizontal arrows. 
Compounds screened, and screening results, are listed in Table S2. 
(B) Chemical structures of the two ROR1-binding ‘hits’ from (A). 
(C) TM shift as a function of GZD824 concentration binding to purified ROR1 pseudokinase 
domain (at 2 µM) using DSF, with curve fit as described in STAR Methods. Mean ± SD is shown 
for three independent experiments. 
(D) Cellular thermal shift assay (CETSA) showing stabilization of ROR1 in cells upon addition of 
ponatinib or GZD824. BaF3-ROR1 cells were treated with 10 µM ponatinib or GZD824, and 
subjected to the noted temperatures as described in STAR Methods. Cell lysates were blotted 
with anti-HA to assess ROR1 levels, and with anti-β-tubulin as a loading control. 
(E) CETSA data as in (D), derived from signal quantification of 3 independent experiments 
(mean ± SD), with curves fit as described in STAR Methods. Band intensities were normalized 
to the non-heated and non-treated sample for each experiment (set at a value of 1). Control 
(grey) curve represents heated samples without added inhibitor. 
See also Figure S6 and Table S2. 
 
FIGURE 7 
Binding of ponatinib and GZD824 to the ROR1 pseudokinase domain 
(A) HDX data for ROR1, comparing exchange differences for 62 peptides with- and without 
added GZD824 (50 µM) at a representative 1 min timepoint. Color coding is shown in the scale 
at bottom, red representing increased HDX upon inhibitor binding, and blue a reduction. Data for 
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selected peptides (i, ii, iii, and iv) are detailed in (B). ROR1 secondary structure is shown at 
top. Values for all time points for three biological replicates are shown in Fig. S7A. 
(B) HDX data for selected peptides showing HDX with- and without inhibitor across 3 biological 
replicates (mean ± SD). Data are shown for ponatinib treatment (solid cyan line) and GZD824 
treatment (dotted cyan line), for peptides marked in (A): i (from helix αC); ii (from β5/αD hinge); 
iii (from β1/β2 loop); and iv (from the activation loop). 
(C) Structure of ponatinib-bound ROR1 pseudokinase, shown in cyan (ponatinib is black), with 
side-chains involved in ponatinib binding detailed in the zoomed view. 
(D) Overlay of the ponatinib-bound ROR1 pseudokinase domain on the ROR2 pseudokinase 
domain, using only the C-lobe to guide overlay. In comparing these structures, DynDom3D 
(Girdlestone and Hayward, 2016) identified an ~20˚ rotation of the N-lobe with respect to the C-
lobe about the yellow near-vertical axis as described in the text. The hinge tyrosine (Y554 in 
ROR1, Y555 in ROR2) and ROR1 αC helices that interact with ponatinib are labeled, and the 
displacement of this tyrosine by ponatinib is depicted with a red arrow. 




Table 1. Crystallization Conditions, Data Collection and Refinement Statistics 
 
 
Protein PTK7 RYK ROR1-ponatinib 
PBD ID 6VG3 6TUA 6TU9 
Crystallization Conditions 11 mg/ml protein, 
100 mM ADA 
(pH 6.5), 100 mM 
(NH4)2SO4, 30% (w/v) 
PEG monoethyl ether 
5000, 20˚C 
11 mg/ml protein, 
100 mM HEPES 
(pH 7.5), 1.5 M 
Li2SO4, 20˚C 
13 mg/ml protein, 
0.5 mM ponatinib, 
100 mM MES 
(pH 7.2), 12% (w/v) 
PEG 20K, 4˚C 
Data Collectiona    
Beamline  APS/NE-CAT 24-ID-C SLS X06SA SLS X06SA 
Date of collection June 20, 2017 December 7, 2018 December 7, 2018 
Wavelength (Å) 0.979 0.99999 0.99999 
Space Group C 2 2 21 I 2 P 21 
Cell Dimensions    
     a, b, c (Å) 95.63, 119.92, 166.52 60.64, 47.24, 152.74 54.29, 85.97, 72.98 
      α, β, γ (°)    90, 90, 90 90.00, 97.64, 90.00 90.00, 91.05, 90.00 
Resolution (Å) 48.7 – 1.95 37.85 – 2.38 39.12 – 1.94 
Completeness 98.5 (97.7) 98.3 (96.3) 98.7 (97.5) 
Redundancy 8.1 (8.1) 3.7 (3.6) 5.0 (5.0) 
Rsym (%) 9.2 (102.1) 6.4 (38.6) 5.8 (52.1) 
I/σ 13.4 (1.9) 8.3 (2.0) 8.0 (2.0) 
CC1/2 b 0.999 (0.74) 1.0 (0.9) 1.0 (0.8) 
Refinement    
Number of reflections 68,916 (9835) 17,213 (1691) 49,066 (4844) 
Rwork/Rfree (%) 18.4/22.9 19.4/24.8 20.9/24.1 
Number of atoms    
       Protein 6516 2270 4000 
       Ions 0 25 0 
       Ligands 0 0 78 
       Water 598 28 94 
Average B factor (Å)    
       Protein 45.5 40.3 47.9 
       Ions - 92.4 - 
       Ligands - - 37.9 
       Water 36.2 33.9 42.0 
Ramachandran favored (%) 96.4 97.6 96.5 
Ramachandran allowed (%) 3.6 2.1 3.5 
Ramachandran outliers (%) 0.0 0.4 0.0 
Bond length rmsd (Å) 0.009 0.008 0.007 
Bond angle rmsd (Å) 1.01 0.88 0.84 
aNumbers in parentheses denote highest resolution shell 








Lead contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Mark A. Lemmon (mark.lemmon@yale.edu). 
 
Materials availability 
Unique and stable reagents generated in this study are available upon request. 
 
Data and code availability 
PDB accession codes for the crystallographic coordinates and structure factors reported in this 
paper are: PDB: 6VG3 (PTK7 pseudokinase domain http://www.rcsb.org/structure/6VG3); 
PDB: 6TUA (RYK pseudokinase domain http://www.rcsb.org/structure/6TUA); PDB: 6TU9 
(ROR1 pseudokinase domain with bound ponatinib http://www.rcsb.org/structure/6TU9). HDX-
MS data and datapoints for all peptides are provided in Table S1 (Excel file). Results from 
the screen in Fig. 6A are provided in Table S2 (Excel file). Source code for determining 
‘exchangeability indices’ in Fig. 4D is available at 
https://github.com/sheetzjb/RTKpseudokinases. Original gel data have been deposited to 
Mendeley Data: https://doi.org/10.17632/65v6bff7bm.1 
 




Spodoptera frugiperda Sf9 cells were propagated at 27˚C with constant shaking at 120 rpm in 
serum-free ESF 921 Insect Cell Culture Medium (Expression Systems) containing 50 U/ml 
penicillin/streptomycin, and were used for production of all proteins except ROR453-752 and 
RYK292-607, for which the TriEx variant of Sf9 cells (EMD Millipore) were used – propagating at 
27˚C with constant shaking at 90 rpm in serum-free Insect-XPRESS Medium (Lonza). All Sf9 
cells were originally established from immature ovaries of female S. frugiperda pupae. 
Mammalian cells 
Mus musculus BaF3 cells (pro B cell line, DSMZ, ACC 300) were grown in RPMI media (Lonza, 
Basel, Switzerland) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml 




Plasmid construction for recombinant protein expression 
Crystallization constructs: PCR was used to amplify DNA encoding residues 774-1069 of human 
PTK7, 453-752 of human ROR1 and 292-607 of human RYK. For PTK7 an N-terminal 
hexahistidine tag plus BamHI and HindIII restriction sites were included, and the fragment was 
subcloned into pFastBac1 (Invitrogen). For ROR1 and RYK, PCR fragments were inserted into 
the vector pFB-6HZB (Invitrogen) via ligation-independent cloning. 
Hydrogen/Deuterium Exchange-Mass Spectrometry constructs: DNA fragments encoding 
residues 457-752 of human ROR1, 318-607 of human RYK (including a sequence encoding an 
N-terminal TEV cleavage site), and 978-1283 of the human insulin receptor were amplified by 
PCR – to include sequence encoding an N-terminal hexahistidine tag and regions overlapping 
with the multiple cloning site of pFastbac1. Insert products and PCR-amplified pFastbac1 vector 
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were digested with DpnI to remove template DNA, and were subsequently ligated using 
NEBuilder HiFi DNA Assembly Cloning Kit. A construct encoding residues 452-753 of human 
ROR2 was generated previously (Artim et al., 2012). 
 
Protein production and purification 
Protein production for crystallization: For expression of PTK7774-1069, Sf9 cells at 2 x 106/ml were 
infected with recombinant baculovirus, and harvested by centrifugation after 3 days. Cells were 
lysed by sonication in Buffer A [500 ml of 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10% (w/v) 
glycerol, 10 mM imidazole, 10 mM 2-mercaptoethanol, 1 mM PMSF, protease inhibitor cocktail 
(Roche)], and the lysate was clarified by centrifugation for 30 min at 16,000 rpm at 4˚C. Clarified 
lysate was then mixed with Ni-NTA (Ni2+-nitrilotriacetate) beads (Qiagen) – pre-washed 3 times 
with Buffer A – for 1 h at 4˚C. Beads were then washed with 50 column volumes of Buffer A, 
and bound PTK7774-1069 was eluted with increasing concentrations of imidazole in Buffer B 
(Buffer A + 400 mM imidazole). Eluted protein was further purified using a Fractogel TMAE 
(trimethylaminoethyl) anion-exchange column (EMD) equilibrated with Buffer AEX [25 mM Tris-
HCl (pH 8.3), 10 mM NaCl, 2 mM DTT (dithiothreitol)] followed by a Fractogel SO3- cation 
exchange column (EMD) equilibrated with Buffer CEX [20 mM MES (pH 6.0), 150 mM NaCl, 2 
mM DTT]. PTK7774-1069 was eluted with a gradient from the starting NaCl concentration in the 
AEX/CEX column buffers to 1 M NaCl. Protein was then subjected to a final step of size-
exclusion chromatography using a Superdex 75 10/300 column (GE Healthcare) equilibrated in 
20 mM HEPES (pH 7.0), 150 mM NaCl, and 2 mM DTT. 
For expressing ROR1 and RYK pseudokinase domains, exponentially growing TriEx cells (2 
x 106/ml) were infected 1:64 with virus stock, incubated for 66 h at 27˚C with constant shaking, 
and harvested by centrifugation. Cells were resuspended in lysis buffer (50 mM HEPES pH 7.4, 
500 mM NaCl, 20 mM imidazole, 0.5 mM TCEP, 5% glycerol) and lysed by sonication. Lysate 
was cleared by centrifugation and loaded onto a Ni NTA column. After washing with lysis buffer, 
the His6-tagged proteins were eluted in lysis buffer containing 300 mM imidazole. N-terminal 
tags were cleaved using TEV protease during a dialysis step (to remove imidazole). 
Contaminating proteins, the cleaved tags and TEV protease were then removed with a second 
Ni-NTA step. Finally, proteins were concentrated and subjected to size exclusion using an S200 
16/600 column (GE Healthcare), from which ROR1 and RYK eluted as expected for monomers. 
Final yields were 2.5 mg/l insect cell medium (ROR1) and 0.4 mg/l insect cell medium (RYK). 
Protein production for HDX-MS: For production of ROR1457–752, ROR2452–753, or RYK318-607, 
Sf9 cells were lysed by sonication in Buffer A [500 ml of 50 mM Tris-HCl (pH 8.0), 300 mM 
NaCl, 10 mM 2-mercaptoethanol, 1 mM PMSF, protease inhibitor cocktail (Roche)]. Lysate was 
clarified by centrifugation for 30 min at 16,000 rpm at 4˚C and loaded onto pre-washed a Ni-
NTA (1 ml per liter of culture) for 1 h at 4˚C. Beads were then washed with 50 column volumes 
of Buffer A, and protein eluted with increasing concentrations of imidazole in Buffer B (Buffer A 
+ 400 mM imidazole). Protein was next loaded onto a Fractogel TMAE (trimethylaminoethyl) 
anion-exchange column (EMD) equilibrated with Buffer AEX [50 mM Tris-HCl (pH 8.0), 20 mM 
NaCl, 2 mM DTT (dithiothreitol)], and eluted with a NaCl gradient up to 1 M. Eluted fractions 
were diluted in Buffer CEX [50 mM MES (pH 6.0), 50 mM NaCl, 2 mM DTT] and loaded onto a 
Fractogel SO3- cation exchange column (EMD) equilibrated with Buffer CEX, and eluted with a 
NaCl gradient in Buffer CEX up to 1 M. Protein was then subjected to size-exclusion 
chromatography using a Superdex 75 10/300 column (GE Healthcare) equilibrated in 20 mM 
HEPES (pH 7.0), 150 mM NaCl, and 100 μM TCEP [tris-(2-carboxyethyl)phosphine]. The PTK7 
pseudokinase for HDX-MS was purified as described above for crystallization. Production of 
IRK978–1283 followed the same procedure as for the RORs and RYK, except that Buffer A 






Crystals of PTK7774-1069 were obtained using the hanging-drop vapor diffusion method, by mixing 
equal volumes of protein and reservoir solutions and equilibrating over the reservoir solution at 
21˚C. The final protein concentration used was 10.5 mg/ml in 20 mM HEPES (pH 7.0), 150 mM 
NaCl, and 2 mM DTT. Crystals were obtained with a reservoir solution of 30% (w/v) PEG 
monomethyl ether 5,000, 100 mM ADA (pH 6.5), and 100 mM (NH4)2SO4 (Jena Bioscience 
JBKinase Screen 3; condition D1). 
Crystals of the RYK pseudokinase domain were also obtained using the sitting-drop vapor 
diffusion method, by transferring 130 nl drops of the RYK protein solutions at 11 mg/ml to a 3-
well crystallization plate (Swissci) mixed with 70 nl precipitant solution (consisting of 100 mM 
HEPES (pH 7.5), 1.5 M Li2SO4) and incubating at 20˚C. Crystals of the ROR1-ponatinib 
complex were obtained using the same method and volumes, but using 13 mg/ml ROR1 
protein, 0.5 mM ponatinib, and a precipitant solution of 100 mM MES (pH 7.2), 12% (w/v) PEG 
20K – and with incubation at 4˚C. Before flash-freezing in liquid nitrogen, PTK7 crystals were 
cryoprotected in reservoir solution containing 10% (w/v) glycerol, and RYK and ROR1-ponatinib 
crystals were cryoprotected in reservoir solution containing 25% ethylene glycol. 
 
Structure determination 
For PTK7, diffraction data were collected at beamline 23ID-C of GM/CA at Advanced Photon 
Source (APS) and were processed using HKL2000. PTK7 crystallized in space group C2221 
with three molecules in the asymmetric unit. Structures were solved by molecular replacement 
with Phaser, using co-ordinates for the MuSK TKD (PDB: 1LUF) as a search model (Till et al., 
2002). Cycles of manual building/rebuilding using Coot (Emsley and Cowtan, 2004) were 
alternated with rounds of refinement using REFMAC (CCP4, 1994), plus composite omit maps 
calculated with CNS. PROCHECK identified no residues in the disallowed region of the 
Ramachandran plot. For RYK and ROR1/ponatinib, data were collected at Swiss Light Source 
(SLS) and analyzed, scaled and merged with Xia2 (Winter et al., 2013). Structures were solved 
by molecular replacement with Phaser using a ROR2 model (PDB: 4GT4) as a template for 
ROR1 (Artim et al., 2012) and an AXL model (PDB: 5TC0) as a template for RYK (Keung et al., 
2017). The resulting models were refined with REFMAC5 (CCP4, 1994) and validated using 
MolProbity (Chen et al., 2010). Data collection and refinement statistics are listed in Table 1. 
 
Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) 
To obtain mass spectra of undeuterated and of D2O-labelled peptides, purified protein 
(IRK978–1283, PTK7774-1069, ROR1457-752, ROR2452–753, or RYK318-607) at 0.4 mg/ml in H2O-based 
buffer (20 mM HEPES pH 7.4, 200 mM NaCl, 100 µM TCEP) was diluted twenty-fold with 
either H2O-containing (undeuterated standards) or D2O-containing (labeling conditions) buffer 
(20 mM HEPES pD 7.4, 200 mM NaCl, 100 µM TCEP using deuterium as solvent) to label 
amide hydrogen atoms (with final 95% D2O concentration). Labeling was performed at 25˚C 
for a range of times (10 s, 1 min, 10 min, 1 h, or 2 h), and the reaction was quenched by 
adding cold (4˚C) 100 mM sodium phosphate buffer at pH 2.4, containing 2 M guanidine 
hydrochloride and 1% formic acid. For investigating the effect of GZD824 or ponatinib binding 
on ROR1, ROR1457-752 (10 µM) was incubated with freshly prepared GZD824 or ponatinib at a 
final inhibitor concentration of 50 μM (and final DMSO concentration of 5% v/v) for 30 min at 
25˚C prior to deuterium labeling. The D2O buffer contained 20 mM HEPES (pD 7.4), 200 mM 
NaCl, 50 μM GZD824 or ponatinib (and a final 5% DMSO), and the labeled sample was 
quenched by adding cold (4˚C) 200 mM sodium phosphate buffer (pH 2.4) containing 2 M 
guanidine hydrochloride and 1% formic acid. Quenched samples were immediately injected 
onto a Waters HDX nanoAcquity UPLC (Waters, Milford, MA) with in-line digestion using an 
Enzymate BEH pepsin column (Waters, Milford, MA). Peptic fragments were trapped on an 
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Acquity UPLC BEH C18 peptide trap and separated on an Acquity UPLC BEH C18 column. 
For IRK samples, a CSH C18 peptide trap and column were instead used for a more optimal 
peptide separation. A 7 min, 5-35% acetonitrile (0.1% Formic acid) gradient was used to 
elute peptides directly into a Waters Synapt G2-Si mass spectrometer in TOF mode – except 
for one biological replicate each of ROR1 unliganded, 5% DMSO, and 50 μM GZD824, which 
were collected using a Waters Xevo G2-XS QTOF mass spectrometer. MSE data were 
acquired with a 15 to 30 V ramp CID for high energy acquisition of product ions as well as 
continuous lock mass (Leu-Enk) for mass accuracy correction. Peptide identification and 
protein sequence coverage maps were obtained from the undeuterated controls. Peptides 
were identified using the ProteinLynx Global SERVER 3.0.3 (PLGS) from Waters. Fully 
deuterated controls were performed by incubating in the presence of 2 M Guanidine-DCl for 
two hours prior to quenching (PTK7) or by incubating in D2O buffer for 2-7 days (ROR1, 
ROR2, RYK, IRK). All deuterium labeling time points and controls were repeated three times. 
Data and statistical analyses were carried out as described previously (Houde et al., 2011). 
Briefly, the deuterium uptake by the identified peptic fragments through increasing 
deuteration time and for the fully deuterated control was determined using DynamX 3.0 
(Waters). The normalized percentage of deuterium uptake at incubation time t (%Dt) at an 
incubation time t for a given peptide was calculated as follows: 
 





With mt being the centroid mass at incubation time t, m0 the centroid mass of the 
undeuterated control and mf the centroid mass of the fully deuterated control. For studies of 
changes in ROR1 dynamics upon inhibitor binding, the percent deuteration difference plots 
Δ%Dexchange (bound-unbound) presented in Fig. 7 were generated by subtracting the 
corresponding percent deuteration at incubation time t calculated for the DMSO control 
(unbound) from that calculated with ponatinib or GZD824 (bound) thus: 
 
𝛥𝛥%𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑒𝑒 = %𝐷𝐷𝑒𝑒,𝑡𝑡(𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏) − %𝐷𝐷𝑒𝑒,𝑡𝑡(𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏) 
 
where x is each peptide, and t is the D2O incubation time. A summary of the HDX-MS data 
collected and the HDX uptake data are included in Table S1 following consensus guidelines 
(Masson et al., 2019). 
 
Differential scanning fluorimetry (DSF) 
For thermal shift assays to study ATP binding in Fig. S4B, proteins were diluted in 20 mM 
HEPES (pH 7.5), 150 mM NaCl, and 100 μM TCEP to a final protein concentration of 5 μM. 
Nucleotide (5 mM) and/or MgCl2 (10 mM) was added. SYPRO Orange (ThermoFisher 
Scientific) was then added (diluting 2500-fold into the sample), and 25 µl of the reaction 
mixtures were transferred to Concord 96-well polycarbonate PCR plates (Bio-Rad) with three 
technical replicates per condition. A Bio-Rad CFX96 Touch Real Time PCR machine was 
then used to monitor fluorescence at 530 nm while the temperature was raised by 1˚C per 
minute from 25˚C to 95˚C, with fluorescence measured at each increment. Fluorescence 
values were then plotted as a function of temperature after normalizing to the maximum 
fluorescence signal. Melting temperatures (TM) were determined as the temperature at half-
maximum fluorescence. Plots were generated using GraphPad Prism and represent the 
mean from three technical replicates. 
For thermal shift assays used for small molecule screening (Fig. 6) and analysis of 
ponatinib binding (Fig. 6C), a 2 µM solution of the relevant purified pseudokinase domain in 
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assay buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 0.5 mM TCEP, 5% glycerol) was mixed 
1:1000 with SYPRO Orange (Millipore Sigma). Test compounds were added to a final 
concentration of 10 µM (containing a final 2% DMSO). 20 µl of each sample were then 
placed in a 96-well plate, and the temperature increased stepwise from 25˚C to 95˚C. 
Fluorescence was monitored using a Mx3005P real-time PCR instrument (Stratagene) with 
excitation and emission filters set to 465 and 590 nm, respectively. Data were analyzed using 
MxPro software. Compound screening was performed as a single shot experiment. Potential 
pseudokinase binders were confirmed by repeating the experiment with an inhibitor 
concentration series (final concentrations up to 25 μM) – as seen for GZD824 in Fig. 6C. 
Plots were generated using GraphPad Prism and represent the mean from three technical 
replicates. 
 
Small molecule screening 
Small molecule screening was performed using the DSF assay described above. Our 
screening collection consisted of the kinase inhibitor library (#L1200 Selleckchem) and FDA-
approved drug library (#L1300 Selleckchem), which includes a total of 1486 compounds. 
Failure to get hits with other pseudokinases does not simply reflect protein stability; the most 
stable Wnt-signaling pseudokinase was PTK7 (TM ~ 59˚C) followed by RYK (54˚C), ROR1 
(53˚C) and ROR2 (51˚C). 
 
Homology models of EphA10 and EphB6 
The crystal structure of EphB3 kinase (PDB: 3ZFY) in the inactive conformation (Overman et al., 
2014) was selected as the template for modeling the inactive conformation of the EphA10 and 
EphB6 pseudokinase domains. After running BLAST for sequence alignment, the top crystal 
structure matches with EphA10 and EphB6 were found to be EphA4 (PDB: 2YGM) and EphB1 
(PDB: 3ZFX) respectively, which were then used as templates for modeling active 
conformations of EphA10 and EphB6 pseudokinase domains. Coordinates of the active and 
inactive template kinases were downloaded from the Protein Data Bank, and missing residues 
were added by generating a homology model of the kinase using its own partial structure as the 
template. Five candidate models were generated from each of the templates by satisfying a set 
of static and dynamic spatial restraints in MODELLER. These restraints are expressed in terms 
of molecular probability density function, or objective function, which is optimized and applied in 
the ranking of the set of models constructed in MODELLER. The stereochemical quality of each 
model was further evaluated using the Discrete Optimized Protein Energy (DOPE) method – an 
atomic distance-dependent statistical potential optimized for model assessment in MODELLER, 
with the lowest DOPE score defining the preferred model. We structurally aligned all of the 
homology models for EphA10 and EphB6 to their template structures using Visual Molecular 
Dynamics (VMD), and generated Root Mean Square Deviation (RMSD) plots to find regions of 
variability. Most variation was seen in the first 50 residues for the homology models of the 
inactive structures of EphA10 and EphB6, so a hybrid approach was used to improve models for 
the inactive EphA10 and EphB6 conformations, where the coordinates for the first 50 residues 
came from the homology model for the active conformation of the kinase, and the rest of the 
coordinates come from the homology model for the inactive conformation. VMD was used to 
display structural models, and MODELLER was used for homology modeling of the 
pseudokinase domains for both EphA10 and EphB6. 
 
BaF3 cell transfections 
For expression in BaF3 cells, human ROR1, ROR2, PTK7 and RYK (or their truncated variants) 
were cloned into the pEFIRES-P vector (Hobbs et al., 1998) and electroporated into BaF3 cells 
using the 4D-Nucleofector X Kit L (Lonza) and a 4D Nucleofector X (Lonza), using program 
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code DS-137. After 72 h, transfected cells were selected with increasing amounts of puromycin 
(0.5-1 µg/ml) for 2 weeks and tested for protein expression by Western blot (Figs. 5 and S5). 
 
Cell viability and cell proliferation 
Cell counts were determined by Trypan-blue exclusion using a Countess II automated cell 
counter (Life Technologies). Cell viability was measured using the CellTiter-Glow 2.0 Assay 
(CTG, Promega, Madison, USA) according to the manufacturer’s instructions. 
 
Western blotting  
Whole cell lysates were prepared by lysing cells in ice cold NP-40 lysis buffer (50 mM Tris-HCl 
pH 7.4, 10% glycerol, 50 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, 20 mM NaF), 
supplemented with protease and phosphatase inhibitor cocktails (Bimake, Houston, TX, USA). 
Cell lysates were incubated 15 min on ice, clarified by centrifugation (4˚C, 20 min, 20,000 x g), 
resuspended in 2 x SDS sample buffer and boiled at 95˚C for 5 min. Samples were separated 
by SDS-PAGE and transferred to nitrocellulose membrane. Blots were blocked (4% BSA in 
0.05% Tween 20 in 1xTBS) at RT for 1 h and incubated with primary antibody at 4˚C overnight. 
Blots were then washed 3 times with TBS/0.1% Tween 20 buffer, and subjected to secondary 
antibodies for 1 h at RT. Blots were scanned with an Odyssey® CLx Imaging System (LI-COR) 
and images analyzed using Image Studio Lite (LI-COR). 
For Western blotting, the following antibodies were used: pAKT (S473, #6942), AKT 
(#9272), pERK1/2 (#9101), ERK1/2 (#4696), PTK7 (#25618), and SRC (#2109) from Cell 
Signaling Technology (Danvers, MA, USA); ROR1 4A5 (#564464) and ROR2 (#565550) from 
BD Biosciences (San Jose, CA, USA); anti-pTYR 4G10 (#05-321) from MerckMillipore; β-tubulin 
(#sc-166729) from Santa Cruz Biotechnology (Dallas, TX, USA); HA (#901513) from BioLegend 
(San Diego, CA). As secondary antibodies, IRDye® 800CW Donkey anti-Mouse IgG or IRDye® 
680RD Donkey anti-Rabbit IgG (LI-COR, Lincoln, NE, USA) were used at 1:10.000 dilution. 
 
Cellular thermal shift assay (CETSA)  
CETSA was carried out according to the protocol described (Martinez Molina et al., 2013). 
Briefly, BaF3-ROR1 cells were treated with control (DMSO) or drug (10 µM) and incubated at 
37˚C for 2 h. Cells were washed once and divided into aliquots with 0.5 x 106 cells each. 
Samples were heated (Bio-Rad T100TM Thermal Cycler) pairwise (control and drug-treated 
samples) for 3 min at 42-60˚C with 2˚C increments between pairs. After heating, cells were kept 
at room temperature for 3 min before transferring to ice. Cells were collected and lysed in Triton 
X100-containing lysis buffer (50 mM Tris-HCl, pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 50 mM NaF) supplemented with protease and phosphatase inhibitor 
cocktails (Bimake, Houston, TX, USA), and were subsequently analyzed by SDS-PAGE and 
Western blotting using anti-HA (ROR1) and β-tubulin antibodies. Protein levels were quantified 
with Image Studio Lite (Li-COR) and normalized to 42˚C samples for both treatments. 
 
in vitro kinase assays 
Kinase assays were performed using either ATP hydrolysis as a readout (ADP-Glo) or 
fluorescence detection of phosphorylation of a peptide. For the ADP-Glo assay (Promega), a kit 
was used as recommended by the manufacturer. Briefly, reactions with 1 µM purified ROR1 
pseudokinase domain or kinase controls (at 1 µM) were set up in kinase assay buffer (20 mM 
HEPES, pH 7.4, containing 10 mM MgCl2, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT) with 
addition of 1 mM ATP and 0.1 mg/ml poly(Glu, Tyr) peptide substrate (Sigma-Aldrich). 
Reactions were incubated for 1 h at ambient temperature, and were then quenched by addition 
of an equal volume of ADP-Glo reagent – unreacted ATP was depleted over the course of 40 
minutes at room temperature. An equal volume of detection reagent was then added to convert 
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ADP in the reaction mixture into newly synthesized ATP, which serves as a substrate for the 
luciferase reaction. Samples were incubated for 1 h at room temperature before luminescence 
measurements were taken in a 384-well plate using a BioTek Synergy 2 Multi-Detection 
Microplate Reader. Experiments were performed in technical triplicate. 
For fluorescent peptide assays, materials from Assay Quant Technologies were used as 
recommended by the manufacturer. Briefly, reactions with 1 µM purified ROR1 pseudokinase 
domain or kinase controls (at 1 µM) were set up in wells of a 384-well plate with the final assay 
conditions: 50 mM HEPES, pH 7.5, containing 10 mM MgCl2, 0.01% Brij-35, 0.1 mg/ml BSA, 
1 mM ATP, and 20 µM peptide substrate sensor (AQT0001) that contains an incorporated Sox 
chromophore (Assay Quant). Reactions were incubated at 30°C for 2 h, and fluorescence 
intensities were collected every 2 min using a BioTek Synergy 2 Multi-Detection Microplate 
Reader. Experiments were performed in technical triplicate. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Structure determination and analysis 
The statistical analysis of the structural models is provided in Table 1. Analysis of the 
molecular contacts and RMSD values were calculated using the CCP4 software package 
(CCP4, 1994).  
 
Analysis of HDX dynamics 
Raw MSE mass spectra of undeuterated controls were used for peptide identification using 
ProteinLynx Global Server 3.0.3 (PLGS) from Waters. MS data from all controls and labeling 
conditions were then processed using DynamX to identify peptic peptides for each condition. 
All raw spectra for each peptide, labeling condition, drug condition, and charge state were 
then manually assessed for quality and for accurate peak assignment, at which point poor 
quality or incorrectly assigned peaks were unassigned. Average mass shifts of centroids and 
their standard deviations were then used to calculate percent uptake for each time point 
relative to a fully deuterated standard as described in Method Details. Uptake plots in Figs. 
4A,C represent standard deviations from three independent labeling experiments for all 
conditions shown. Uptake plots in Fig. 7B represent mean ± SD from three independent 
protein preparations, for each of which three independent labelling experiments were 
performed in all conditions. 
For ‘exchangeability indices’ (Fig. 4D), an R script was written to first calculate an 
average percent exchange for each residue in each pseudokinase (and IRK) at each time 
point. The value assigned to each residue was the mean (per residue) percent exchange 
seen for all peptides containing that residue. In parallel, each residue in each pseudokinase 
was assigned a corresponding homologous residue in IRK (based on sequence alignments). 
For the position corresponding to each residue in IRK, the mean (± SD) percent exchange 
was calculated across the 4 pseudokinases (ROR1, ROR2, RYK, PTK7) for each time point. 
This pseudokinase ‘exchangeability index’ value was then compared with the exchange value 
assigned to the corresponding residue in IRK – with deviations reported in terms of number 
of standard deviations (σ) away from the average pseudokinase uptake. Differences between 
pseudokinase exchangeability index and IRK exchange for each residue were averaged 
across all time points to depict areas that show more (orange) or less (black) HDX in 
pseudokinases than in IRK, as shown in Fig. 4D. 
 
Western blot image processing 
Raw images from the LI-COR Odyssey were imported in Adobe Photoshop, and linear 
contrast stretching was manually applied using the ‘Levels’ function – so that the darkest 
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points of the images are black, and background is brought into the visible grey scale so that 
all features are registered. 
 
Cell proliferation assays 
All cell proliferation assays experiments were analyzed using Prism v8.0 software 
(GraphPad, San Diego, CA, USA). Cell proliferation data are represented as mean ± SD from 
four independent experiments each performed in technical triplicate. Statistical significance 
was determined using two-tailed t-tests. Two-sided p values were used to determine 
statistical significance, set as follows: *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
 
Cellular thermal shift assays 
All cellular thermal shift experiments were analyzed using Prism v8.0 software (GraphPad, 
San Diego, CA, USA). Individual bands were quantified using Image Studio Lite software and 
all values (band intensities) were normalized to unheated control sample (no inhibitor 
treatment) that denotes relative band intensity value of one. Standard deviation (SD) was 
calculated using three independent experiments. Curve fitting was done in Prism using 
Boltzmann sigmoidal algorithm. For concentration-dependent CETSA in Fig. S6, a constant 
heating temperature of 48˚C was chosen based on the results from Fig. 6E. All values (band 
intensities) were normalized to heated samples without inhibitor. Curve fitting was done in 




SUPPLEMENTAL EXCEL TABLE TITLES 
 
TABLE S1 – Related to Figures 4 and 7. 
HDX-MS summary and uptake data. 
Experimental details are listed for all HDX-MS experiments performed in this study, and the 
uptake data for each peptide reported are included. 
 
 
TABLE S2 – Related to Figure 6. 
Compound list and results for screening to identify pseudokinase-binding molecules. 
A library of 1486 small molecules consisting largely of protein kinase inhibitors or FDA approved 
drugs and their respective effects on the differential scanning fluorometry-based Tm shift values 
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Figure S1 – Related to Figure 1. 
Amino acid sequence alignment of RTK pseudokinase domains alongside IRK, EGFR, and 
protein kinase A (PKA) 
Highly conserved residues across all kinases/pseudokinases are boxed in grey; sequence variations 
in pseudokinases for key conserved residues are in bold red text. Secondary structure elements are 
noted, as are the catalytic and activation loop regions as well as the G-rich loop, HRD, and DFG 
motifs. Putative regulatory activation-loop tyrosine residues (in the YxxxYY motif) are in bold blue text, 






   IRK   ITLLRELGQGSFGMVYEGNA-RDIIK-GEAETRVAVKTVNESAS--LRERIEFLNEASVMKGFTCH-HVVR   1061 
  PTK7   LQPITTLGKSEFGEVFLAKA-QGL-EEGVAETLVLVKSLQSKDE---QQQLDFRRELEMFGKL-NHANVVR   860 
  ROR1   VRFMEELGECAFGKIYKGHL-YLPG-MDHA-QLVAIKTLKDYNN--PQQWTEFQQEASLMAEL-HHPNIVC   537 
  ROR2   VRFMEELGEDRFGKVYKGHL-FGPAPGEQT-QAVAIKTLKDKAE--GPLREEFRHEAMLRARL-QHPNVVC   538 
   RYK   ITLKDVLQEGTFGRIFHGIL-IDEKDPNK-EKQAFVKTVKDQAS--EIQVTMMLTESCKLRGL-HHRNLLP   395 
EphA10   VTLERSLGGGRFGELCCGCL-QLP-GRQEL--LVAVHMLRDSAS--DSQRLGFLAEALTLGQF-DHSHIVR   708 
 EphB6   IKIEEVIGTGSFGEVRQGRL-QPR-GRREQ--TVAIQALWAGGA--ESLQMTFLGRAAVLGQF-QHPNILR   733 
 ErbB3   LRKLKVLGSGVFGTVHKGVW-IPEGESIKI--PVCIKVIEDKSG--RQSFQAVTDHMLAIGSL-DHAHIVR   754 
  EGFR   FKKIKVLGSGAFGTVYKGLW-IPEGEKVKI--PVAIKELREATS--PKANKEILDEAYVMASV-DNPHVCR   752 





   IRK   LLGV-VSKGQPTLVVMELMAHGDLKSYLRSLRP------EAENN-PGRPPPTLQEMIQMAAEIADGMAYLN   1124 
  PTK7   LLGL-CREAEPHYMVLEYVDLGDLKQFLRISK-------SKDEK-LKSQPLSTKQKVALCTQVALGMEHLS   922 
  ROR1   LLGA-VTQEQPVCMLFEYINQGDLHEFLIMRSPHSDVGCSSDEDGTVKSSLDHGDFLHIAIQIAAGMEYLS   607 
  ROR2   LLGV-VTKDQPLSMIFSYCSHGDLHEFLVMRSPHSDVG-STDDDRTVKSALEPPDFVHLVAQIAAGMEYLS   607 
   RYK   ITHVCIEEGEKPMVILPYMNWGNLKLFLRQCK-----LVEANNP----QAISQQDLVHMAIQIACGMSYLA   457 
EphA10   LEGV-VTRGSTLMIVTEYMSHGALDGFLRRHEG----------------QLVAGQLMGLLPGLASAMKYLS   762 
 EphB6   LEGV-VTKSRPLMVLTEFMELGPLDSFLRQREG----------------QFSSLQLVAMQRGVAAAMQYLS   787 
 ErbB3   LLG--LCPGSSLQLVTQYLPLGSLLDHVRQHRG----------------ALGPQLLLNWGVQIAKGMYYLE   807 
  EGFR   LLGICLT--STVQLITQLMPFGCLLDYVREHKD----------------NIGSQYLLNWCVQIAKGMNYLE   805 






   IRK   AKKFVHRDLAARNCMVAHDFTVKIG GDF MTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSF   1195 
  PTK7   NNRFVHKDLAARNCLVSAQRQVKVSALGLSKDVYNSEYYHFRQ-AWVPLRWMSPEAILEGDFSTKSDVWAF   992 
  ROR1   SHFFVHKDLAARNILIGEQLHVKISDLGLSREIYSADYYRVQSKSLLPIRWMPPEAIMYGKFSSDSDIWSF   678 
  ROR2   SHHVVHKDLATRNVLVYDKLNVKISDLGLFREVYAADYYKLLGNSLLPIRWMAPEAIMYGKFSIDSDIWSY   678 
   RYK   RREVIHKDLAARNCVIDDTLQVKITDNALSRDLFPMDYHCLGDNENRPVRWMALESLVNNEFSSASDVWAF   528 
EphA10   EMGYVHRGLAARHVLVSSDLVCKISGFGRGPRDRSEAVYTTMS-GRSPALWAAPETLQFGHFSSASDVWSF   832 
 EphB6   SFAFVHRSLSAHSVLVNSHLVCKVARLGHSPQGPSC-----------LLRWAAPEVIAHGKHTTSSDVWSF   847 
 ErbB3   EHGMVHRNLAARNVLLKSPSQVQVADFGVADLLPPDDKQLLYSEAKTPIKWMALESIHFGKYTHQSDVWSY   878 
  EGFR   DRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY   876 






   IRK   GVVLWEITSLAEQPYQGLSNEQVLKFVMDGG-YLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLL     1263 
  PTK7   GVLMWEVFTHGEMPHGGQADDEVLADLQAGKARLPQPEGCPSKLYRLMQRCWALSPKDRPSFSEIASAL     1061 
  ROR1   GVVLWEIFSFGLQPYYGFSNQEVIEMVRKRQ-LLPCSEDCPPRMYSLMTECWNEIPSRRPRFKDIHVRL     746 
  ROR2   GVVLWEVFSYGLQPYCGYSNQDVVEMIRNRQ-VLPCPDDCPAWVYALMIECWNEFPSRRPRFKDIHSRL     746 
   RYK   GVTLWELMTLGQTPYVDIDPFEMAAYLKDGY-RIAQPINCPDELFAVMACCWALDPEERPKFQQLVQCL     596 
EphA10   GIIMWEVMAFGERPYWDMSGQDVIKAVEDGF-RLPPPRNCPNLLHRLMLDCWQKDPGERPRFSQIHSIL     900 
 EphB6   GILMWEVMSYGERPYWDMSEQEVLNAIEQEF-RLPPPPGCPPGLHLLMLDTWQKDRARRPHFDQLVAAF     915 
 ErbB3   GVTVWELMTFGAEPYAGLRLAEVPDLLEKGE-RLAQPQICTIDVYMVMVKCWMIDENIRPTFKELANEF     946 
  EGFR   GVTVWELMTFGSKPYDGIPASEISSILEKGE-RLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEF     944 
   PKA   GVLIYE-MAAGYPPFFADQPIQIYEKIVSGK--VRFPSHFSSDLKDLLRNLLQVDLTKRFGNLKNGVND     290 
β1 β2 β3 αB αC
β4 β5 αD αE
















Figure S2 – Related to Figure 2. 
Comparison of hydrophobic spines in the RTK pseudokinases 
Top row: Cartoon representation of the catalytically active kinases PKA (white; PDB: 1ATP) and IRK 
(black) in its active (PDB: 1IR3) and inactive (PDB: 1IRK) conformations. Residues comprising the 
catalytic spine (C-spine) and the regulatory spine (R-spine) for each domain are shown in surface 
representation and colored yellow or red, respectively. Both are complete in the active kinases – with 
the C-spine completed by the adenine ring of ATP. In inactive IRK, F1151 of the DFG motif instead 
occupies the adenine ring position in the C-spine. Upon activation loop phosphorylation and ligation of 
the ATP-binding site, F1151 flips from this position towards the aC helix to complete the R-spine. The 
‘gatekeeper’ residue (homologous to threonine 315 in ABL) is shown for each domain in sphere 
representation, and ATP or AMP-PNP is also shown where bound. 
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Middle row: Pseudokinase domains from PTK7 (slate blue), ROR2 (magenta; PDB: 4GT4), and RYK 
(green). The C-spine is completed in each case by aromatic side-chains that take the place of an ATP 
ligand. In PTK7 and ROR2, the leucine that replaces the DFG phenylalanine (L949 in PTK7’s ‘ALG’ 
motif, and L634 in ROR2’s ‘DLG’ motif) abuts the C-spine, but does not contribute to its completion 
like F1151 does in inactive IRK. Although these residues do not contribute to C-spine completion, they 
also do not contribute to the R-spine – which is broken in both cases. In RYK, the C-spine is 
complete, and the R-spine is broken because it lacks an equivalent hydrophobic residue to the DFG 
phenylalanine (replaced by N of DNA, which is in displaced from the spine. 
 
Bottom: The C- and R-spines of ErbB3 (orange; PDB: 4RIW) are shown, both complete, with an 




Figure S3 – Related to Figure 3. 
Rotation of the N-lobe and position of the aC helix in the RTK pseudokinases 
The N-lobes of the pseudokinase domains from (A): PTK7 (slate blue), (B): ROR2 (magenta), 
(C): RYK (green), and (D): active IRK (black; PBD: 1IR3) were individually overlaid on inactive IRK 
(white; PDB: 1IRK) based on superimpositions of the kinase C-lobes – to inspect differences in N-lobe 
orientation as a result of rotation about the b5/aD hinge. The C-lobe of only inactive IRK is 
represented (for clarity). Helix aC is colored red in each domain. 
In (A), the aC helix is clearly ‘out’ for inactive IRK and ‘in’ for PTK7. In addition, the entire N-lobe 
has undergone a rotation about the b5/aD hinge (marked in red) that also causes Y877 (marked) to 
project into the ATP-binding site (which it occludes) – whereas the corresponding IRK residue (L1078) 
projects away from the ATP-binding site. In (B), aC is ‘out’ for both ROR2 and inactive IRK, but ROR2 
also displays the N-lobe rotation about the b5/aD hinge seen for PTK7 – in this case causing the 
Y555 side-chain of ROR2 to occlude the ATP-binding site. In (C), RYK displays an aC ‘in’ 
conformation (like PTK7), but its N-lobe has not undergone rotation about the b5/aD hinge, so the 
Y413 side-chain aligns with IRK L1078 and projects away from the ATP-binding site. In (D), active 
and inactive IRK are overlaid – with no N-lobe rotation, but a clear aC displacement.  
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Figure S4 – Related to Figure 4. 
Occlusion of the nucleotide-binding site prevents ATP-binding in Wnt-binding pseudokinases 
(A) Detailed structural view of the occluded ATP-binding sites of PTK7 (slate blue), ROR2 (magenta), 
RYK (green), and inactive IRK (black; PBD: 1IRK). Residues contributing to steric occlusion of the 
nucleotide-binding site are labelled and shown in both stick representation with a transparent surface 
and mesh for emphasis, with AMP-PNP placed based on superimposition with active IRK (PDB: 1IR3) 
– to highlight the degree of occlusion. 
(B) DSF analysis of the melting temperatures of IRK and the PTK7, ROR2, RYK, and ROR1 
pseudokinases in the presence and absence of 5 mM ATP and/or MgCl2. For IRK, the presence of 
ATP and Mg2+ results in a leftward shift (ΔTM ~ 3.5°C) in the melting curve, indicating decreased IRK 
stability upon Mg2+-ATP binding. By contrast, the melting curves of PTK7, ROR2, RYK, and ROR1 
were unchanged. Mutating the activation loop aspartate in ROR2 to alanine (D644A) – analogous to 
the IRK D1161A mutation that increases ATP-binding affinity ~20-fold even without phosphorylation 
(Ablooglu et al., 2001) – had no effect on the ATP-binding properties of ROR2. Curves represent 
means of three technical replicates. 
 6 
 
Figure S5 – Related to Figure 5. 
Analysis of protein expression and cell survival following stable expression of ROR1, ROR2 
and PTK7 in BaF3 cells. 
(A) BaF3 parental and BaF3-ROR1, BaF3-ROR2 and BaF3-PTK7 stable clones were analyzed for 
expression of ROR1, ROR2 and PTK7 by Western blotting with the indicated antibodies and b-tubulin 
as loading control. 
(B) Ability of BaF3 cells expressing ROR1, ROR2 or PTK7 to proliferate in the absence of IL3 or 
Wnt5a. Relative cell proliferation at the indicated times was measured using the CellTiter-Glow 2.0 
Assay, and expressed as a fold increase over the proliferation seen for parental BaF3 cells. Data are 
represented as mean ± SD, for 3 biological repeats. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05. 
(C) Wnt5a stimulation increases ERK phosphorylation in BaF3-ROR1, but not BaF3-ROR2 cells. 
Experiments were performed as in Fig. 5C, with 50 ng/ml Wnt5a, and detection of ROR1 and ROR2 
protein levels using anti-HA blotting. A representative of three independent experiments is shown.	
(D) Endpoint in vitro kinase assay, assessing phosphorylation of poly(Glu,Tyr) substrate during a 1 h 
incubation at room temperature for monomeric wild-type EGFR kinase (kcat approximately 2 min-1), 
IRK, and ROR1 . See STAR Methods for experimental details. Data are presented as mean ± SD of 
experimental triplicates. 
(E) Time courses of in vitro kinase activity towards a sulfonamido-oxine (Sox) chromophore-
incorporated fluorescent peptide substrate for 1 µM EGFR wild-type kinase domain (kcat approximately 
2 min-1) and 1 µM ROR1 pseudokinase domain. See STAR Methods for experimental details. Data 
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Figure S6 – Related to Figure 6. 
CETSA analysis for concentration-dependent binding of ponatinib or GZD824 to ROR1 
(A) Representative Western blots showing stabilization of ROR1 expressed in BaF3 cells by 
increasing doses of ponatinib or GZD824. Cells were incubated at 48˚C as described in STAR 
Methods prior to immunoblotting to quantitate remaining non-degraded protein. 
(B) Quantification of Western blots from (A). Band intensities were normalized to the intensity from the 
non-treated sample for each experiment. Data are presented as means ± SD, n ≥ 3 independent 
experiments (biological repeats). 
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Figure S7 – Related to Figure 7. 
Ponatinib/GZD824 is associated with altered ROR1 dynamics and can inhibit Wnt5a signaling 
(A) Summary of exchange differences observed in the ROR1 pseudokinase in the presence or 
absence of 50 µM GZD824 as monitored by HDX-MS. Data are shown for all time points. Peptides 
recovered across each time point are represented by horizontal lines, color coded based on the 
difference in percent exchange relative to a fully deuterated standard. As shown in the scale at 
bottom, red represents an HDX increase upon inhibitor binding, and blue represents a reduction in 
exchange. ROR1 secondary structure is shown at top. Results represent the mean of three biological 
repeats. 
(B) HDX results from Fig. S7A (1 min time point) are plotted on the ponatinib-bound ROR1 
pseudokinase domain data using the same color scheme as in (A), with blue representing less 
exchange, and red more exchange, upon inhibitor binding. 
(C) Structural superimposition of the ponatinib-bound ROR1 pseudokinase (cyan) on the ponatinib-
bound ABL kinase domain (yellow; PDB 3IK3), with ponatinib shown in black when bound to ROR1 
and in white when bound to ABL. Ponatinib docks into the ROR1 pseudokinase domain in virtually the 
same (type II) orientation as seen with ABL. 
(D) Adding ponatinib or GZD824 at 1 µM to BaF3 cells expressing full-length ROR1 inhibits the 
Wnt5a-dependent increases in ERK, AKT, and SRC phosphorylation shown in Fig. 5C. Cells were 
stimulated with 50 ng/ml Wnt5a for 0, 0.5, 2, or 4 h in the absence or presence of the inhibitors. Cell 
lysates were then blotted with anti-ROR1 (to assess total ROR1 levels), and with anti-pERK, anti-
ERK, anti-pAKT, anti-AKT, and anti-b-tubulin (as a loading control) as described in STAR Methods. 
Blot is representative of three biological replicates. 
 
